Ann H Partridge1, R Bryan Rumble1, Lisa A Carey1, Steven E Come1, Nancy E Davidson1, Angelo Di Leo1, Julie Gralow1, Gabriel N Hortobagyi1, Beverly Moy1, Douglas Yee1, Shelley B Brundage1, Michael A Danso1, Maggie Wilcox1, Ian E Smith1. 1. Ann H. Partridge, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center; Beverly Moy, Massachusetts General Hospital, Boston, MA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; Michael A. Danso, Virginia Oncology Associates, Norfolk, VA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Nancy E. Davidson, University of Pittsburgh Cancer Institute/University of Pittsburgh Medical Center, Pittsburgh, PA; Angelo Di Leo, Sandro Pitigliani Medical Oncology Unit, Prato, Italy; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Douglas Yee, University of Minnesota/Masonic Cancer Center, Minneapolis, MN; Shelley B. Brundage, Patient Representative, Washington, DC; Maggie Wilcox, Independent Cancer Patients' Voice; and Ian E. Smith, Royal Marsden Hospital, London, United Kingdom.
Abstract
PURPOSE: To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer. METHODS: A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1993 through to current was completed. Outcomes of interest included survival, progression-free survival, response, quality of life, and adverse effects. Guideline recommendations were evidence based and were agreed on by the Expert Panel via consensus. RESULTS: Seventy-nine studies met the inclusion criteria, comprising 20 systematic reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and subsequent treatment. These trials form the evidence base for the guideline recommendations. RECOMMENDATIONS: Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor-positive metastatic breast cancer unless improvement is medically necessary (eg, immediately life-threatening disease). Single agent is preferable to combination chemotherapy, and longer planned duration improves outcome but must be balanced against toxicity. There is no single optimal first-line or subsequent line chemotherapy, and choice of treatment will be determined by multiple factors including prior therapy, toxicity, performance status, comorbid conditions, and patient preference. The role of bevacizumab remains controversial. Other targeted therapies have not so far been shown to enhance chemotherapy outcome in HER2-negative breast cancer.
PURPOSE: To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer. METHODS: A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1993 through to current was completed. Outcomes of interest included survival, progression-free survival, response, quality of life, and adverse effects. Guideline recommendations were evidence based and were agreed on by the Expert Panel via consensus. RESULTS: Seventy-nine studies met the inclusion criteria, comprising 20 systematic reviews and/or meta-analyses, 30 trials on first-line treatment, and 29 trials on second-line and subsequent treatment. These trials form the evidence base for the guideline recommendations. RECOMMENDATIONS: Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor-positive metastatic breast cancer unless improvement is medically necessary (eg, immediately life-threatening disease). Single agent is preferable to combination chemotherapy, and longer planned duration improves outcome but must be balanced against toxicity. There is no single optimal first-line or subsequent line chemotherapy, and choice of treatment will be determined by multiple factors including prior therapy, toxicity, performance status, comorbid conditions, and patient preference. The role of bevacizumab remains controversial. Other targeted therapies have not so far been shown to enhance chemotherapy outcome in HER2-negative breast cancer.
Authors: Helene Svensson; Zakaria Einbeigi; Hemming Johansson; Thomas Hatschek; Yvonne Brandberg Journal: Breast Cancer Res Treat Date: 2010-08-03 Impact factor: 4.872
Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Martin R Stockler; Vernon J Harvey; Prudence A Francis; Michael J Byrne; Stephen P Ackland; Bernie Fitzharris; Guy Van Hazel; Nicholas R C Wilcken; Peter S Grimison; Anna K Nowak; M Corona Gainford; Akiko Fong; Lisa Paksec; Tatiana Sourjina; Diana Zannino; Val Gebski; R John Simes; John F Forbes; Alan S Coates Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544
Authors: J-U Blohmer; P Schmid; J Hilfrich; K Friese; A Kleine-Tebbe; H Koelbl; H Sommer; G Morack; M B Wischnewsky; W Lichtenegger; S Kuemmel Journal: Ann Oncol Date: 2010-01-20 Impact factor: 32.976
Authors: Alan M Keller; Robert G Mennel; Vassilis A Georgoulias; Jean-Marc Nabholtz; Aura Erazo; Anna Lluch; Charles L Vogel; Manfred Kaufmann; Gunther von Minckwitz; I Craig Henderson; Lillian Mellars; Leila Alland; Craig Tendler Journal: J Clin Oncol Date: 2004-10-01 Impact factor: 44.544
Authors: L Manso; F Moreno; R Márquez; B Castelo; A Arcediano; M Arroyo; A I Ballesteros; I Calvo; M J Echarri; S Enrech; A Gómez; R González Del Val; E López-Miranda; M Martín-Angulo; N Martínez-Jañez; C Olier; P Zamora Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: V Lambert-Obry; A Gouault-Laliberté; A Castonguay; G Zanotti; T Tran; M Mates; J Lemieux; P Chabot; C Prady; F Couture; J Lachaine Journal: Curr Oncol Date: 2018-08-14 Impact factor: 3.677
Authors: José Baselga; Claudio Zamagni; Patricia Gómez; Begoña Bermejo; Shigenori E Nagai; Bohuslav Melichar; Arlene Chan; Lászlo Mángel; Jonas Bergh; Frederico Costa; Henry L Gómez; William J Gradishar; Clifford A Hudis; Bernardo L Rapoport; Henri Roché; Patricia Maeda; Liping Huang; Gerold Meinhardt; Joshua Zhang; Lee S Schwartzberg Journal: Clin Breast Cancer Date: 2017-05-22 Impact factor: 3.225